This was not an efficacy halt, and that is the whole problem. The DSMB can request a halt when EITHER arm is doing bad for safety reasons. That is what happened. The problem is that the efficacy data is now somewhat in question. I do agree, this is not an FDA problem (unless one implies they need stronger controls on DSMBs).